FDA warned Rite-Kem over inadequate current good manufacturing practice testing of over-the-counter drugs, including hand sanitizers and antimicrobial products.
What happened
FDA inspected Rite-Kem's drug manufacturing facility in Tupelo, Mississippi, from September 9 to 12, 2024. The agency found that Rite-Kem released over-the-counter drug batches without adequate finished-product identity, strength, or microbial testing; did not adequately test components such as glycerin for diethylene glycol or ethylene glycol, or an incoming active ingredient for methanol; and lacked adequate quality-unit oversight.
What FDA found
Rite-Kem did not test each finished drug batch for the identity and strength of active ingredients or for microorganisms before release.
21 CFR 211.165(a)Rite-Kem did not perform identity testing on each component lot and relied on supplier certificates of analysis without establishing their reliability.
21 CFR 211.84(d)(1) and 211.84(d)(2)Rite-Kem did not test each glycerin lot for diethylene glycol or ethylene glycol using the United States Pharmacopeia identity test.
21 CFR 211.84(d)(1) and 211.84(d)(2)Rite-Kem did not test an incoming active ingredient for methanol, a toxic impurity.
21 CFR 211.84(d)(1) and 211.84(d)(2)Rite-Kem's quality unit did not ensure adequate process and equipment validation, written procedures, employee training, batch records, stability testing, or cleaning and cleaning validation.
21 CFR 211.22; 211.100(a); 211.22(d); 211.25(a); 211.188(b); 211.166(a); 211.67(a)-(b)Rite-Kem's drug products are adulterated because its manufacturing methods, facilities, or controls do not conform to CGMP.
section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B)
What FDA wants
FDA tells Rite-Kem to respond in writing within 15 working days with corrective action plans, testing and supplier-qualification information, and risk assessments, including diethylene glycol and ethylene glycol test results within 30 calendar days. Rite-Kem must also notify FDA before resuming drug manufacturing.
Who should pay attention
- brands or retailers that buy Rite-Kem over-the-counter drugs
- contract manufacturers of hand sanitizers or antimicrobial products
- buyers and suppliers of glycerin or other high-risk drug components
This is a summary. Read the original letter on fda.gov.